Skip to main content
Midas Edge

Atara Biotherapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

ATRA$8.10-1.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

(In thousands)

Accumulated
Common · Additional · Other · Total
Stock · Paid-in · Comprehensive · Accumulated · Stockholders’
For the Nine Months Ended September 30, 2025 · Shares · Amount · Capital · Income (Loss) · Deficit · Equity (Deficit)
Balance as of January 1, 20255,859$1$1,957,261$8$(2,054,553)$(97,283)
RSU settlements, net of shares withheld65—————
Stock-based compensation expense——4,209——4,209
Net (loss) income————38,01038,010
Unrealized gain (loss) on available-for-sale securities———(8)—(8)
Balance as of March 31, 20255,924$1$1,961,470$—$(2,016,543)$(55,072)
Issuance of pre-funded warrants to purchase common stock through an underwritten registered direct offering, net of offering costs of $522834—14,843——14,843
RSU settlements, net of shares withheld220—(1)——(1)
Issuance of common stock pursuant to employee stock awards——1——1
Stock-based compensation expense——2,801——2,801
Net (loss) income————2,3872,387
Balance as of June 30, 20256,978$1$1,979,114$—$(2,014,156)$(35,041)
Issuance of common stock through ATM facilities, net of commissions and offering costs of $48125$1,471——1,471
RSU settlements, net of shares withheld106—————
Issuance of common stock pursuant to employee stock awards1—12——12
Stock-based compensation expense——1,225——1,225
Net (loss) income————(4,303)(4,303)
Unrealized gain (loss) on available-for-sale securities———2—2
Balance as of September 30, 20257,210$1$1,981,822$2$(2,018,459)$(36,634)
Accumulated
Common · Additional · Other · Total
Stock · Paid-in · Comprehensive · Accumulated · Stockholders’
For the Nine Months Ended September 30, 2024 · Shares · Amount · Capital · Income (Loss) · Deficit · Equity (Deficit)
Balance as of January 1, 20244,258$—$1,870,123$(204)$(1,969,150)$(99,231)
Issuance of pre-funded warrants to purchase common stock through a registered direct offering, net of offering costs of $177—$—$14,823$—$—$14,823
Issuance of common stock through ATM facilities, net of commissions and offering costs of $168493—9,312——9,312
RSU settlements, net of shares withheld63—(6)——(6)
Stock-based compensation expense——8,397——8,397
Net (loss) income————(31,752)(31,752)
Unrealized gain (loss) on available-for-sale securities———149—149
Balance as of March 31, 20244,814$—$1,902,649$(55)$(2,000,902)$(98,308)
RSU settlements, net of shares withheld81—(1)——(1)
Issuance of common stock pursuant to employee stock awards9—113——113
Stock-based compensation expense——6,336——6,336
Net (loss) income————(19,049)(19,049)
Unrealized gain (loss) on available-for-sale securities———41—41
Balance as of June 30, 20244,904$-$1,909,097$(14)$(2,019,951)$(110,868)
Issuance of common stock and pre-funded warrants to purchase common stock through a registered direct offering, net of offering costs of $220759$1$35,779——35,780
RSU settlements, net of shares withheld77—————
Stock-based compensation expense——6,422——6,422
Net (loss) income————(21,909)(21,909)
Unrealized gain (loss) on available-for-sale securities———36—36
Balance as of September 30, 20245,740$1$1,951,298$22$(2,041,860)$(90,539)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.